DEEJ(000423)2025-03-17 12:25Financial Performance - The company's operating revenue for 2024 reached ¥5,920,785,955.41, representing a 25.57% increase compared to ¥4,715,265,729.50 in 2023[19] - Net profit attributable to shareholders was ¥1,557,000,775.65, a 35.29% increase from ¥1,150,878,550.46 in the previous year[19] - The net profit after deducting non-recurring gains and losses was ¥1,441,714,437.09, up 33.17% from ¥1,082,628,480.93 in 2023[19] - The basic earnings per share increased to ¥2.42, a rise of 35.20% from ¥1.79 in 2023[19] - The weighted average return on equity improved to 14.60%, up from 11.12% in the previous year, marking an increase of 3.48%[19] - Total assets at the end of 2024 were ¥13,087,136,728.33, a decrease of 1.65% from ¥13,306,306,533.41 at the end of 2023[19] - The net assets attributable to shareholders decreased by 3.81% to ¥10,310,173,764.03 from ¥10,719,014,633.60 in 2023[19] - The cash flow from operating activities was ¥2,170,810,025.93, reflecting an 11.13% increase compared to ¥1,953,438,009.50 in 2023[19] Dividend Distribution - The company plans to distribute a cash dividend of ¥12.70 per 10 shares, based on a total of 643,976,824 shares[5] - The profit distribution plan for 2024 proposes a cash dividend of 12.70 RMB per 10 shares, totaling approximately 818 million RMB, representing 99.70% of the undistributed net profit for the year[83] - The total cash dividend amount, including other methods, is 893,723,011.48 CNY, representing 100% of the profit distribution total[129] Research and Development - R&D investment increased by 27.63% to ¥209,941,773.61 in 2024, accounting for 3.55% of operating revenue[58] - The number of R&D personnel rose to 338, a 4.64% increase from 2023, with a notable 31.46% increase in master's degree holders[58] - The company is currently conducting 32 R&D projects, focusing on quality standards and evidence-based research for new product development[58] - The company has initiated 8 new drug research projects under its "dual-wheel drive" strategy, aimed at expanding its product pipeline[58] - The company is actively working on 14 projects to establish quality standards for potential high-value products, enhancing its competitive edge in the market[58] Market Strategy and Product Development - The company plans to implement the "1238" strategy to enhance its core business and drive innovation in traditional Chinese medicine[28] - The company launched new products, including "Zhuangben" brand and various health supplements targeting men's health, showcasing its commitment to product diversification[32] - The company aims to establish a demonstration base for the inheritance and innovation of traditional Chinese medicine culture, enhancing its brand recognition and cultural significance[35] - The company is focusing on expanding its product offerings and enhancing its research and development capabilities in the pharmaceutical sector[103] - The company is actively pursuing new strategies for market expansion and product innovation to enhance its competitive edge[103] Corporate Governance - The company has established a complete and independent business system, ensuring autonomy in operations and decision-making[92] - The company maintains a clear separation of assets, personnel, finance, and operations from its controlling shareholder[92] - The board of directors consists of 9 members, including 3 independent directors, meeting legal requirements[87] - The company has a dedicated financial department with an independent accounting system, ensuring no interference from the controlling shareholder[92] - The company adheres to strict information disclosure regulations, ensuring timely and accurate communication with investors[90] Environmental Sustainability - The company has maintained compliance with environmental regulations, holding a valid pollution discharge permit until November 5, 2029[145] - Wastewater treatment facilities are in place, with two plants treating different types of wastewater, ensuring compliance with discharge standards[147] - The company reported no exceedance of pollutant discharge limits, with COD and ammonia nitrogen levels well below regulatory thresholds[146] - The company has implemented a comprehensive self-monitoring plan for wastewater and air emissions, achieving a 100% compliance rate in monitoring and reporting[148] - The company is committed to environmental sustainability, with treatment standards exceeding regulatory requirements[147] Management Changes - The company reported a significant leadership change with the appointment of Cheng Jie as President, effective January 10, 2022, and his term will end on October 22, 2024[97] - The company experienced a turnover in its board of directors, with multiple resignations including Bai Xiaosong and Cui Xingpin, effective March 2023 and August 2023 respectively[97] - The company announced the resignation of Chairman Bai Xiaosong effective October 22, 2024, due to job changes[98] - President Cheng Jie will continue to serve as the Party Secretary and a board member after resigning from the presidency on October 22, 2024[98] - The company is focusing on maintaining a stable management team, with several key positions remaining filled through 2027, which may support strategic initiatives[96] Financial Management - The company maintained a debt-to-asset ratio of 21.05% and had cash reserves of 5.015 billion RMB at the end of the year[82] - The company has no significant related party transactions during the reporting period[169] - The company has not reported any significant mergers or acquisitions during the reporting period[198] - The company has maintained a good integrity status with no significant debts or court judgments against it[168] Shareholder Information - The total number of shares is 643,976,824, with 100% being unrestricted shares[196] - The largest shareholder, China Resources Dong'a Ejiao Co., Ltd., holds 23.50% of shares, totaling 151,351,731 shares[199] - The top two shareholders, China Resources Dong'e Ejiao Co., Ltd. and China Resources Pharmaceutical Investment Co., Ltd., collectively hold 215,711,473 shares, accounting for 33.49% of the total share capital[200]